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The Medicines and Related Substances Act1 (the Act) provides 
for the registration of medicine by the Medicines Control 
Council (MCC). In terms of the Medicines and Related 
Substances Amendment Bill, signed but not yet proclaimed, 
the MCC will shortly be replaced by the South African Health 
Products Regulatory Authority (SAPHRA). Despite major 
changes in the administrative structure, SAPHRA will probably 
have the same functions as the MCC. Section 14 of the Act 
forbids the sale of unregistered medicine.
Compared with the USA, for example, issues surrounding 
the off-label use of medication have received little attention 
in South Africa. The term ‘off-label’ means that the medicine 
is used in another way or for an indication other than those 
specified in the conditions of registration of the medicine and 
as reflected in its labelling.2 It does, however, not necessarily 
imply that the medication is not effective or is unsafe to be 
used in this way.3 Off-label use has become an important part 
of mainstream, legitimate medical practice worldwide4  and 
is especially common in oncology, obstetrics, paediatrics, 
infectious diseases (notably HIV) and rare diseases.5 
Depending on the circumstances, off-label use of medication 
can vary from being experimental or controversial to standard 
practice and even state-of-the-art treatment.4
The off-label use of any medication obviously carries a 
higher risk for the patient and the medical practitioner than its 
registered use, and therefore extra care should be taken. From 
a legal/ethical point of view the off-label use of medication 
represents a delicate balance between the statutory regulation 
of medication (which aims at safeguarding patients against 
unsafe and ineffective medications) and the prerogative of a 
physician to prescribe medication that, in his or her medical 
opinion, will be beneficial to the patient.6 Legal implications 
such as when the off-label use of medication will be negligent 
and when not, and whether the patient must be informed 
that the medicine is used off-label, are dealt with in a separate 
contribution in this journal.7 
Regulatory framework
In a further article in this journal, health care professionals 
highlight a situation where a life-sustaining drug, Prostin, 
which is in daily (off-label) use as an emergency treatment 
for infants to maintain the patency of the ductus arteriosus, 
unexpectedly became in short supply.8 The question arises as 
to whether the dilemma occasioned by unawareness of the 
shortage was created by the regulatory framework.
In South Africa various stipulations of the Act and regulation 
45(3)9 prohibit the dissemination of information regarding the 
off-label use of medication. Regulation 45(3) stipulates that no 
advertisement for medicine may contain a statement regarding 
its safety, quality or efficacy that deviates from the purpose 
for which and the manner in which it was registered. Section 
20(1)(b) forbids any advertisement from making any claim 
regarding the therapeutic efficacy and effect other than that for 
which it is registered (and as indicated in the labelling thereof). 
The definitions of ‘advertisement’ and ‘public’ as contained in 
section 1 of the Act are very wide and the latter is defined so as 
to include medical health professionals. In effect no written or 
oral information regarding the safety, quality or efficacy of off-
label use of medicine may be disseminated to the public or to 
medical practitioners by the manufacturer or distributor. 
It is submitted that, according to the ordinary meaning of the 
words in these stipulations, a general notification to medical 
practitioners that the medication will be in short supply, 
whether it is used off-label or not, does not fall thereunder and 
is therefore not prohibited thereby. On common law grounds 
a strong argument can even be made out that there is a legal 
duty on the pharmaceutical company in these circumstances 
to warn medical practitioners in time of any shortage of this 
medication. The following factors serve as indicators of the 
existence of such a duty: when used in this way, Prostin is 
an emergency, life-sustaining drug; a very vulnerable group 
is involved; no similar drug is available; the pharmaceutical 
company gains financially in the selling of this product; the 
information that the medicine will be in short supply is in the 
exclusive possession of the pharmaceutical company; and the 
pharmaceutical company is aware of the off-label use of the 
medication (a  children’s hospital is hardly likely to use a drug 
registered to induce labour other than in an off-label way!). 
To these factors the constitutional imperative as contained 
in section 28(2) of the Constitution of the Republic of South 
Africa,10 namely that a child’s best interests are of paramount 
importance in every matter concerning the child, can be added. 
Whether a legal duty to notify (of shortages) exists will 
depend on the circumstances of each case. It would for 
example make a difference if the medication is for chronic use 
in the treatment of ulcers and other similar medication is also 
readily available. It would however be good business practice 
to send out this type of notice in any event.
It is true that pharmaceutical companies are obliged to 
adhere to the Act and its regulations strictly and that there 
can in some instances be a very thin line between promotion 
and mere notification. There is also a draft SA Code of Practice 
for the Marketing of Medicines in existence which is yet to 
be published. The wording thereof is in accordance with the 
Act and its regulations. Lastly, it is important to note that 
pharmaceutical companies should, in their contracts with 
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suppliers (for example of packaging material), make provision 
for timeous notification of inability to supply.
Dissemination of information on  
off-label use
Physicians become acquainted with off-label uses of medication 
through professional medical literature, presentations and 
peer lectures at conferences, medical research and advice from 
colleagues. There are two diverging views, both with pros and 
cons, on whether pharmaceutical companies should be allowed 
to distribute medical journal articles and scientific reference 
publications on off-label uses for approved drugs.
The main argument against allowing dissemination of this 
kind of information by pharmaceutical companies is that it 
significantly reduces the medicines regulatory authority’s 
ability to protect the public against unsafe and ineffective 
medicines. Anecdotal data are not the equivalent of clinical 
tests.6 
On the other hand it is of the utmost importance that medical 
practitioners have the latest accurate and non-misleading 
medical and scientific information on medication, including 
off-label uses, when deciding on a patient’s treatment.11 By 
missing one or two important articles, the practitioner may be 
unable to choose the best option.
In the USA section 401 of the FDA Modernization Act of 
1997 (FDAMA) greatly eased restrictions on drug promotions. 
Although section 401 expired in 2006, current policy carries 
forward many of its provisions. FDA policy currently prohibits 
the direct promotion of products for off-label uses, but the 
FDA recently published guidelines for the distribution of 
medical journal articles and scientific reference publications on 
unapproved new uses for approved drugs.11,12 The distribution 
of this type of information is prohibited in South Africa and 
the position is therefore more comparable with that existing in 
European countries.
Testifying before the American Congress, senator Bill Frist, 
himself a medical practitioner and one of the authors of section 
401 of the FDAMA, said: ‘If a conscientious doctor were to read 
two articles before retiring every night, he would have fallen 
550 years behind in his reading at the end of the first year.’13
Many aspects surrounding the off-label use of medication 
should be debated in South Africa in order to decide whether 
a via media cannot be found. Attention should be given to the 
systematic collection of post-marketing data on the prevalence 
of the off-label use of medicines and its harms and benefits. 
Medical associations and institutions should also provide 
medical practitioners with guidelines on the lawful and ethical 
off-label use of medication.
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